Multi-target Compounds against Trypanosomatid Parasites and Mycobacterium tuberculosis

被引：0

作者：

Gomes, Midiane Correia ^{[1
]}

Padilha, Emanuelly Karla Araujo ^{[1
]}

Angelo Diniz, Gustavo Rafael ^{[1
]}

Gomes, Edilma Correia ^{[1
]}

da Silva Santos-Junior, Paulo Fernando ^{[1
]}

Zhan, Peng ^{[2
]}

Ferreira da Siva-Junior, Edeildo ^{[1
]}

机构：

[1] Univ Fed Alagoas, Inst Chem & Biotechnol, Res Grp Biol & Mol Chem, Campus AC Simoes, BR-57072970 Maceio, AL, Brazil

[2] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Key Lab Chem Biol,Minist Educ,Cheeloo Coll Med, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China

来源：

CURRENT DRUG TARGETS | 2024年 / 25卷 / 09期

关键词：

Multi-target compounds; trypanosoma; leishmaniasis; tuberculosis; neglected tropical diseases; monotherapy; IN-VITRO; DIHYDROFOLATE-REDUCTASE; LEISHMANIA-DONOVANI; DUAL INHIBITORS; DRUG TARGET; DISEASE; BRUCEI; SINGLE; TRANSMISSION; FEXINIDAZOLE;

D O I：

10.2174/0113894501306843240606114854

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Multi-target drug treatment has become popular as a substitute for traditional monotherapy. Monotherapy can lead to resistance and side effects. Multi-target drug discovery is gaining importance as data on bioactivity becomes more abundant. The design of multi-target drugs is expected to be an important development in the pharmaceutical industry in the near future. This review presents multi-target compounds against trypanosomatid parasites (Trypanosoma cruzi, T. brucei, and Leishmania sp.) and tuberculosis (Mycobacterium tuberculosis), which mainly affect populations in socioeconomically unfavorable conditions. The article analyzes the studies, including their chemical structures, viral strains, and molecular docking studies, when available. The objective of this review is to establish a foundation for designing new multi-target inhibitors for these diseases.

引用

页码：602 / 619

页数：18

共 101 条

[1] Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity [J].

Aguilera, Elena ;

Varela, Javier ;

Birriel, Estefania ;

Serna, Elva ;

Torres, Susana ;

Yaluff, Gloria ;

de Bilbao, Ninfa Vera ;

Aguirre-Lopez, Beatriz ;

Cabrera, Nallely ;

Diaz Mazariegos, Selma ;

Tuena de Gomez-Puyou, Marieta ;

Gomez-Puyou, Armando ;

Perez-Montfort, Ruy ;

Minini, Lucia ;

Merlino, Alicia ;

Cerecetto, Hugo ;

Gonzalez, Mercedes ;

Alvarez, Guzman .

CHEMMEDCHEM, 2016, 11 (12) :1328-1338

[2] Covalent Inhibitors for Neglected Diseases: An Exploration of Novel Therapeutic Options [J].

Alves, Erick Tavares Marcelino ;

Pernichelle, Filipe Gomes ;

Nascimento, Lucas Adriano ;

Ferreira, Glaucio Monteiro ;

Ferreira, Elizabeth Igne .

PHARMACEUTICALS, 2023, 16 (07)

[3]

[Anonymous], 2013, DNDi Fexinidazole for Chagas

[4]

[Anonymous], 2023, WHO Tuberculosis

[5]

[Anonymous], 2024, The Global Health Observatory

[6]

[Anonymous], 2023, WHO Leishmaniasis

[7] Neglected Tropical Diseases and Mental Health: Progress, Partnerships, and Integration [J].

Bailey, Freddie ;

Eaton, Julian ;

Jidda, Muhammad ;

van Brakel, Wim H. ;

Addiss, David G. ;

Molyneux, David H. .

TRENDS IN PARASITOLOGY, 2019, 35 (01) :23-31

[8] Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis [J].

Banerjee, Deb Ranjan ;

Biswas, Rupam ;

Das, Amit K. ;

Basak, Amit .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 100 :223-234

[9]

Belllera C.L., 2019, Silico Drug Des, P625, DOI [10.1016/b978-0-12-816125-8.00021-3, DOI 10.1016/B978-0-12-816125-8.00021-3]

[10] Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease [J].

Beltran-Hortelano, Ivan ;

Alcolea, Veronica ;

Font, Maria ;

Perez-Silanes, Silvia .

BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 58

← 1 2 3 4 5 6 7 8 9 10 →